Send to a friend
Age-related macular degeneration (AMD)
Diabetic retinopathy
Diabetic macular edema
Ocular neurodegeneration
Retinal vein occlusion
Dry eye syndrome
Ocular inflammation
Ocular allergy
Ocular pain
Ocular surgery
Corneal wound healing
Visual defects
Orphan diseases
Retinal ischemia
Capillary nonperfusion
Ocular neovascularization
Ocular angiogenesis
Eye edema
Retinitis pigmentosa
Home » Services » Clinical trials » Overview
Clinical trials in ophthalmology


Iris Pharma is a leading, therapeutically specialized Contract Research Organization (CRO) focused on ophthalmology clinical trials. We carry out clinical studies and medico marketing studies throughout Western and Eastern Europe, North Africa, India and North America:

Extensive experience, trained staff and an excellent knowledge of the pharmaceutical industry coupled with a unique expertise in ophthalmology allows us to anticipate the risks, efficiently run and complete trials and ensure your success.



To help you progress a new ocular drug from its conception to marketing approval, regardless of the stage in development that you access our services by:

  • Providing either a full service or customized solutions tailored to your specific needs
  • Producing the most reliable, accurate and high-quality data
  • Reducing the time to perform a study and cutting costs, maximizing resources

We have built well-established relationships with leading professors in ophthalmology, academic centers and investigators, allowing us to choose the best route for your study and increase our effectiveness in recruiting patients.



Iris Pharma works for more than 210 international pharmaceutical and biotechnology industries, research institutes and medical device companies of all sizes. They have chosen to work with us at different levels of the clinical drug development process to bring their drug to market faster.



The clinical outsourcing service of Iris Pharma started in 1994 with the society Clirophtha. Clirophtha was a clinical research organization dedicated to ophthalmology clinical trials in Europe and North America and focusing on eye health care. On Dec 23rd 2007, Iris Pharma merged with Clirophtha. This merger establishes the first global drug-development services provider to be totally dedicated to ophthalmology and offering a complete range of services to biotechnology and pharmaceutical companies worldwide. As well as a global overview of the whole drug development process, the cumulative expertise and experience from both companies guarantees that the new Iris Pharma has excellent knowledge of each stage of drug development, from preclinical formulation and in vivo research to Phase IV and medico-marketing surveys.